BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees stock options to purchase an aggregate of 48,700 shares, and restricted stock units (RSUs) covering an aggregate of 34,000 shares, of BioCryst common stock. The options and RSUs were granted as of December 29, 2023, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Related news for (BCRX)
- Breaking News: MoBot’s Latest Update as of 05/05/25 03:00 PM
- Today’s Top Performers: MoBot’s Market Review 05/05/25 02:00 PM
- BioCryst Pharmaceuticals Soars with Stellar Q1 2025 Results, Raises ORLADEYO Guidance, and Achieves Profitability Ahead of Schedule
- BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
- BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting